Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0JR9V
|
|||
Former ID |
DIB009055
|
|||
Drug Name |
JBP-1
|
|||
Synonyms |
Trypsinogen/chymotrypsinogen/amylase (metastatic cancer), Propanc
Click to Show/Hide
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1], [2] | |
Company |
Propanc Pty Ltd
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Alpha-glucosidase (GLA) | Target Info | Modulator | [1], [2] |
Cationic trypsinogen (PRSS1) | Target Info | Modulator | [1], [2] | |
Chymotrypsin (CTR) | Target Info | Modulator | [1], [2] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Pancreatic secretion | ||||
Protein digestion and absorption | ||||
Influenza A | ||||
Reactome | Activation of Matrix Metalloproteinases | |||
Cobalamin (Cbl, vitamin B12) transport and metabolism | ||||
WikiPathways | Activation of Matrix Metalloproteinases |
References | Top | |||
---|---|---|---|---|
REF 1 | US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. | |||
REF 2 | EP patent application no. 2490711, A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.